BIO-TECHNE CORP

Insider sale by BIO‑TECHNE CEO Kelderman Kim shows routine liquidity, not distress, keeping the company’s steady growth and investor confidence high.

Baumgartner’s mixed buy‑sell on Bio‑Techne signals cautious optimism amid the pending Merck acquisition, hinting at post‑merger upside while hedging short‑term risk.